Journal of Clinical Oncology | 2019
Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.
Abstract
e21050Background: As immunotherapeutics take longer time to show clinical efficacy compared with chemotherapy and targeted therapy, it is critical to select patients with low tumor growth rate (TGR...